FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034339200> ?p ?o ?g. }

• W2034339200 endingPage "1485" @default.
• W2034339200 startingPage "1480" @default.
• W2034339200 abstract "Purpose To report clinical outcomes and early and late complications in 264 hormone-naïve patients with low- and intermediate-risk prostate cancer treated with high-dose-rate brachytherapy (HDR-BT) in combination with external-beam radiotherapy (EBRT). Methods and Materials Between February 2000 and July 2007, 264 patients underwent HDR-BT in combination with EBRT as a treatment for their low- to intermediate-risk prostate cancer. The HDR-BT was performed using ultrasound-based implantation. The total HDR-BT dose was 18 Gy in 3 fractions within 24 h, with a 6-h minimum interval. The EBRT started 2 weeks after HDR-BT and was delivered in 25 fractions of 1.8 Gy to 45 Gy within 5 weeks. Results After a mean follow-up of 74.5 months, 4 patients (1.5%) showed prostate-specific antigen progression according to the American Society for Radiation Oncology definition and 8 patients (3%) according to the Phoenix definition. A biopsy-proven local recurrence was registered in 1 patient (0.4%), and clinical progression (bone metastases) was documented in 2 patients (0.7%). Seven-year actuarial freedom from biochemical failure was 97%, and 7-year disease-specific survival and overall survival were 100% and 91%, respectively. Toxicities were comparable to other series. Conclusions Treatment with interstitial HDR-BT plus EBRT shows a low incidence of late complications and a favorable oncologic outcome after 7 years follow-up. To report clinical outcomes and early and late complications in 264 hormone-naïve patients with low- and intermediate-risk prostate cancer treated with high-dose-rate brachytherapy (HDR-BT) in combination with external-beam radiotherapy (EBRT). Between February 2000 and July 2007, 264 patients underwent HDR-BT in combination with EBRT as a treatment for their low- to intermediate-risk prostate cancer. The HDR-BT was performed using ultrasound-based implantation. The total HDR-BT dose was 18 Gy in 3 fractions within 24 h, with a 6-h minimum interval. The EBRT started 2 weeks after HDR-BT and was delivered in 25 fractions of 1.8 Gy to 45 Gy within 5 weeks. After a mean follow-up of 74.5 months, 4 patients (1.5%) showed prostate-specific antigen progression according to the American Society for Radiation Oncology definition and 8 patients (3%) according to the Phoenix definition. A biopsy-proven local recurrence was registered in 1 patient (0.4%), and clinical progression (bone metastases) was documented in 2 patients (0.7%). Seven-year actuarial freedom from biochemical failure was 97%, and 7-year disease-specific survival and overall survival were 100% and 91%, respectively. Toxicities were comparable to other series. Treatment with interstitial HDR-BT plus EBRT shows a low incidence of late complications and a favorable oncologic outcome after 7 years follow-up." @default.
• W2034339200 created "2016-06-24" @default.
• W2034339200 creator A5001534857 @default.
• W2034339200 creator A5012348926 @default.
• W2034339200 creator A5034618363 @default.
• W2034339200 creator A5040740354 @default.
• W2034339200 creator A5049762337 @default.
• W2034339200 creator A5054564717 @default.
• W2034339200 creator A5063247179 @default.
• W2034339200 date "2012-08-01" @default.
• W2034339200 modified "2023-10-17" @default.
• W2034339200 title "High-Dose-Rate Brachytherapy and External-Beam Radiotherapy for Hormone-Naïve Low- and Intermediate-Risk Prostate Cancer: A 7-Year Experience" @default.
• W2034339200 cites W1978960711 @default.
• W2034339200 cites W1992020401 @default.
• W2034339200 cites W1997716779 @default.
• W2034339200 cites W2002607625 @default.
• W2034339200 cites W2014228954 @default.
• W2034339200 cites W2030891824 @default.
• W2034339200 cites W2056643793 @default.
• W2034339200 cites W2089778115 @default.
• W2034339200 cites W2095375190 @default.
• W2034339200 cites W2108118386 @default.
• W2034339200 cites W2108479568 @default.
• W2034339200 cites W2121495561 @default.
• W2034339200 cites W2124537997 @default.
• W2034339200 cites W2131034864 @default.
• W2034339200 cites W2148117492 @default.
• W2034339200 cites W2152171586 @default.
• W2034339200 doi "https://doi.org/10.1016/j.ijrobp.2011.10.055" @default.
• W2034339200 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22285661" @default.
• W2034339200 hasPublicationYear "2012" @default.
• W2034339200 type Work @default.
• W2034339200 sameAs 2034339200 @default.
• W2034339200 citedByCount "28" @default.
• W2034339200 countsByYear W20343392002013 @default.
• W2034339200 countsByYear W20343392002014 @default.
• W2034339200 countsByYear W20343392002015 @default.
• W2034339200 countsByYear W20343392002016 @default.
• W2034339200 countsByYear W20343392002017 @default.
• W2034339200 countsByYear W20343392002018 @default.
• W2034339200 countsByYear W20343392002019 @default.
• W2034339200 countsByYear W20343392002020 @default.
• W2034339200 countsByYear W20343392002021 @default.
• W2034339200 crossrefType "journal-article" @default.
• W2034339200 hasAuthorship W2034339200A5001534857 @default.
• W2034339200 hasAuthorship W2034339200A5012348926 @default.
• W2034339200 hasAuthorship W2034339200A5034618363 @default.
• W2034339200 hasAuthorship W2034339200A5040740354 @default.
• W2034339200 hasAuthorship W2034339200A5049762337 @default.
• W2034339200 hasAuthorship W2034339200A5054564717 @default.
• W2034339200 hasAuthorship W2034339200A5063247179 @default.
• W2034339200 hasConcept C121608353 @default.
• W2034339200 hasConcept C126322002 @default.
• W2034339200 hasConcept C126838900 @default.
• W2034339200 hasConcept C126894567 @default.
• W2034339200 hasConcept C2775908122 @default.
• W2034339200 hasConcept C2775934546 @default.
• W2034339200 hasConcept C2776235491 @default.
• W2034339200 hasConcept C2777416452 @default.
• W2034339200 hasConcept C2780192828 @default.
• W2034339200 hasConcept C2989005 @default.
• W2034339200 hasConcept C509974204 @default.
• W2034339200 hasConcept C71924100 @default.
• W2034339200 hasConceptScore W2034339200C121608353 @default.
• W2034339200 hasConceptScore W2034339200C126322002 @default.
• W2034339200 hasConceptScore W2034339200C126838900 @default.
• W2034339200 hasConceptScore W2034339200C126894567 @default.
• W2034339200 hasConceptScore W2034339200C2775908122 @default.
• W2034339200 hasConceptScore W2034339200C2775934546 @default.
• W2034339200 hasConceptScore W2034339200C2776235491 @default.
• W2034339200 hasConceptScore W2034339200C2777416452 @default.
• W2034339200 hasConceptScore W2034339200C2780192828 @default.
• W2034339200 hasConceptScore W2034339200C2989005 @default.
• W2034339200 hasConceptScore W2034339200C509974204 @default.
• W2034339200 hasConceptScore W2034339200C71924100 @default.
• W2034339200 hasIssue "5" @default.
• W2034339200 hasLocation W20343392001 @default.
• W2034339200 hasLocation W20343392002 @default.
• W2034339200 hasOpenAccess W2034339200 @default.
• W2034339200 hasPrimaryLocation W20343392001 @default.
• W2034339200 hasRelatedWork W1979374145 @default.
• W2034339200 hasRelatedWork W2102167265 @default.
• W2034339200 hasRelatedWork W2148869351 @default.
• W2034339200 hasRelatedWork W2566665866 @default.
• W2034339200 hasRelatedWork W2788839829 @default.
• W2034339200 hasRelatedWork W2804276825 @default.
• W2034339200 hasRelatedWork W3015759778 @default.
• W2034339200 hasRelatedWork W3107045007 @default.
• W2034339200 hasRelatedWork W3159943067 @default.
• W2034339200 hasRelatedWork W4206581437 @default.
• W2034339200 hasVolume "83" @default.
• W2034339200 isParatext "false" @default.
• W2034339200 isRetracted "false" @default.
• W2034339200 magId "2034339200" @default.
• W2034339200 workType "article" @default.